I wanted to take a moment and post this for everyones information...
The AIDS Drug Assistance Program (ADAP) provides HIV/AIDS related prescription drugs to uninsured and underinsured individuals living with HIV/AIDS.
|ADAP funds are used to provide medications to treat HIV disease, or to prevent the serious deterioration of health, including measures for the prevention and treatment of opportunistic infections. As a payer of last resort, ADAP only serves individuals who have neither public nor private insurance or cannot get all of their medication needs met through their insurance payer.|
As of December 16 there are currently 4,732 people currently waiting for drug coverage assistance within 9 states....
This is a shocking number, if you are uncertain of what this means... Currently nearly 5000 people are in need of medication to survive and live a normal life. Sadly they can not afford medication and with the major changes in our health care reform they are struggling to survive! I want to make sure everyone can see this, and we all need to work together to find a solution to help everyone!
Fatigue has historically been a common problem among people living with HIV, with prevalence rates approaching 90 percent in some studies. Untreated fatigue can lead to unemployment and social isolation, and it can reduce people’s ability to effectively care for themselves.
To examine fatigue in HIV disease in the modern treatment era, Eefje Jong, MD, of Slotervaart Hospital in Amsterdam, and her colleagues analyzed data from 42 studies published between January 1996 and August 2008. In addition to wanting to learn more about the prevalence of fatigue in more recent years, the researchers set out to understand the factors—including demographic, physiological, psychological and HIV-specific issues—associated with the condition. They also hoped to gain a better sense of the most effective treatment modalities for the condition.
In previous studies, researchers have found that between 20 and 60 percent of people with chronic HIV infection, and up to 85 percent of people with an AIDS diagnosis, have suffered from fatigue at one time or another. In the studies reviewed for Jong and her colleagues’ analysis, fatigue prevalence rates ranged from 33 to 88 percent.
The demographic factors most consistently predictive of fatigue were younger age and unemployment. The authors hypothesized that older people might report less fatigue because they had more effective coping strategies or more time to adjust to medication regimens. Studies that examined race, sex and income were not consistent, though lower income was associated with greater fatigue in at least one study.
In terms of HIV-related issues, CD4 and viral load were not consistently linked with fatigue, though people with more HIV-related symptoms were more likely to have the condition. Studies on comorbid conditions—such as diabetes and hepatitis B or C—were mixed, with some studies finding a connection with fatigue and others showing no connection at all.
Surprisingly, body weight and composition appeared to have no bearing on fatigue, nor did blood levels of proteins related to inflammation, such as interleukin-6 (IL-6) or tumor necrosis factor (TNF) alpha. Some studies showed that lower testosterone levels predicted fatigue, but others did not.
Of all the factors considered, psychological disorders—particularly depression and anxiety—had the strongest and most consistent connection with fatigue. Sleep problems also predicted fatigue. Though the total hours a person slept didn’t have an impact, people who napped during the daytime were more likely to suffer with the problem.
Finally, while a number of treatments for fatigue were explored in the studies, medication was not consistently helpful. Medications with the strongest evidence of fatigue treatment were testosterone and psychostimulants, including Adderall (dextroamphetamine) and Ritalin (methylphenidate hydrochloride). Non-medicinal interventions were more helpful, however, especially cognitive behavioral therapy.
Graded exercise therapy (GET) is another possible option to fight fatigue. With GET, a person logs his or her daily activity and increases it to the point where the exercise begins to worsen symptoms. GET has been successful in HIV-negative people with chronic fatigue syndrome, but no good recent studies focused on HIV-positive people. Though exercise and fatigue studies have been conducted in people with HIV, the authors chose not to include any of them in their analysis, because none used a validated instrument for assessing fatigue either before or during the exercise intervention.
“Currently the evidence for interventions with medication is not strong,” the authors said. “Behavioral interventions and GET seem more promising.”
Because fatigue is so common, and so dramatically reduces a person’s quality of life, the authors urge care providers to assess their patients for the condition. The researchers state that “in case of fatigue, clinicians should not search only for physical mechanisms, but should question depression and anxiety in detail.”
Finally, the authors are calling on researchers to develop an evidence-based approach to screening and treating fatigue in people with HIV.
Search: Fatigue, HIV, Eefje Jong, depression, anxiety, race, Adderall, Ritalin, psychostimulants, testosterone, graded exercise therapy, GED, psychological
What are your thoughts? Feedback? Have you experienced this before?
The Ford Foundation launched a $25 million initiative for locations and groups with high HIV/AIDS rates, which include the District of Columbia and nine Southern states, as well as African Americans, Latinos and women nationwide.
Many of these communities rank the lowest in federal funds spent on people living with HIV/AIDS, including prevention and treatment access.
The foundation will disburse $5 million a year for the next five years to organizations that fight stigma, expand effective AIDS responses from federal and state governments, and educate policymakers and the public about how HIV disproportionately affects certain communities.
“This initiative aims not only to help stop the spread of HIV, but also to address the stigma and discrimination that allowed the epidemic to grow in these communities in the first place,” said Luis A. Ubinas, president of the Ford Foundation.
The community grants were made possible through a separate grant from pharmaceutical company Bristol-Myers Squibb (BMS) to the NAF. BMS and the NAF have been collaborating to find ways to break down barriers to access to care for people living with HIV/AIDS. This collaboration is one of the key components of Positive Charge, a Bristol-Myers Squibb initiative launched in December 2009 that has three main goals: enabling people living with HIV/AIDS to access care and treatment; contributing to the scientific agenda; and demonstrating advocacy leadership.
Also on May 13, Anthony C. Hooper, president of Bristol-Myers Squibb and Kandy Ferree, president and CEO of the National AIDS Fund, and other partners, along with representatives from two of the new grantees, participated in a panel discussion at the White House on “the role of public and private partnerships in the three-pillared National HIV/AIDS Strategy (NHAS), and how this important collaboration addresses the NHAS pillar ‘to increase access to care and optimize health outcomes.’”
This is a huge success!!! I strongly suggest anyone in need of medication assistance, look into this further.